Cytospire Therapeutics
Latest round
- Series A
Last raised
- May 2026
Total raised
- $83M
Investors
- 10
About Cytospire Therapeutics
Cytospire Therapeutics Limited is a biopharmaceutical company focused on developing innovative multispecific antibodies to enhance cancer therapy efficacy. Based in London, UK, it aims to harness immune systems for improved patient outcomes.d T cell engagers in cancer therapy. The company was founded in 2023 by Natalie Mount (CEO) and Mark Uden (CTO) and is headquartered in London, UK.d T cell engagers in cancer therapy. These innovative products harness the innate and adaptive immune systems, providing a more targeted and safer alternative to existing CD3-based engagers. By directing key effector cells to combat cancer, Cytospire addresses various cancer types and improves patient outcomes through its advanced therapeutic solutions. The company generates revenue through partnerships with pharmaceutical companies and healthcare providers, and potentially direct B2B sales of its therapeutic products once commercially available. Revenue strategies may include subscription models for ongoing access to novel therapies or milestone payments associated with successful clinical advancements.d T cell engagement, are expected to command premium pricing due to their novel technology and therapeutic potential. The company aims to introduce new products targeting various cancer types and is exploring expansion into North America, Europe, and Asia.
Who invested in Cytospire Therapeutics
10 investors across 1 round
See all investors in Cytospire Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 5, 2026
Amount
$83M
Investors
Questions about Cytospire Therapeutics
Who invested in Cytospire Therapeutics?
Cytospire Therapeutics has 10 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cytospire Therapeutics raised?
Cytospire Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cytospire Therapeutics last raise money?
Cytospire Therapeutics's most recent round on record is a Series A, in May 2026.
What does Cytospire Therapeutics do?
Cytospire Therapeutics Limited is a biopharmaceutical company focused on developing innovative multispecific antibodies to enhance cancer therapy efficacy.
Where is Cytospire Therapeutics headquartered?
Cytospire Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Cytospire Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Cytospire Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Cytospire Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.